This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull
by Zacks Equity Research
Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing
by Zacks Equity Research
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout
by Zacks Equity Research
The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.
NEOGEN's (NEOG) New Test to Aid in Detecting Cancer-Causing Toxin
by Zacks Equity Research
NEOGEN's (NEOG) latest test is expected to simplify the process of milk testing as well as detecting lower levels of the carcinogenic metabolite Aflatoxin M1.
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
Integra (IART) Preliminary Q4 Reported Sales Show Recovery
by Zacks Equity Research
Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
by Zacks Equity Research
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.
Thermo Fisher (TMO) Rides on End Market Growth Amid Pandemic
by Zacks Equity Research
Thermo Fisher (TMO) launches Amplitude Solution to automate high-throughput PCR-based testing and significantly expands capacity for viral transport media production in Europe.
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results
by Zacks Equity Research
Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2020 result driven mainly by da Vinci procedure volume growth.
Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
by Zacks Equity Research
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
STERIS (STE) to Expand Product Suite Via Cantel Medical Buyout
by Zacks Equity Research
STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.
Zacks.com featured highlights include: IDEXX Laboratories, AGCO, D.R. Horton and MSCI
by Zacks Equity Research
Zacks.com featured highlights include: IDEXX Laboratories, AGCO, D.R. Horton and MSCI
Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
Abbott (ABT) to Expand in Booming TBI Space on New Approval
by Zacks Equity Research
If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
by Zacks Equity Research
Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
4 of the Best Stocks to Buy for Solid Earnings Growth in 2021
by Tirthankar Chakraborty
Earnings growth is considered the most important variable in influencing the share price. Notably, some of the stocks that boast of superb earnings growth include D.R. Horton (DHI) and MSCI.
Hologic (HOLX) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.
Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.
by Zacks Equity Research
Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.
National Vision (EYE) Rides on Comps Growth Amid COVID-19 Woes
by Zacks Equity Research
National Vision's (EYE) Eyeglass pumps sales are robust driven by increases in both customer transactions and average ticket.